Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Branded, Generics), By Type (Bisphosphates, Parathyroid Hormone Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2024

Description

Osteoporosis Drugs Market Growth & Trends:

The global osteoporosis drugs market size is expected to reach USD 18.80 billion by 2030 and is projected to grow at a CAGR of 3.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Osteoporosis Drugs Market Report Highlights:

Branded drugs held the dominant share of the product segment in 2023. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy
Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies
In 2023, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics
Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care
The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Product Code: GVR-1-68038-762-9

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Global Osteoporosis Drugs Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Global Osteoporosis Drugs Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Global Osteoporosis Drugs Market: Drug Class Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Osteoporosis Drugs Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
4.3. Branded
- 4.3.1. Branded Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Generics
- 4.4.1. Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Osteoporosis Drugs Market: Type Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Osteoporosis Drugs Market: Type Movement Analysis, 2023 & 2030 (USD Million)
5.3. Bisphosphonates
- 5.3.1. Bisphosphonates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Parathyroid Hormone Therapy
- 5.4.1. Parathyroid Hormone Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Calcitonin
- 5.5.1. Calcitonin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Selective Estrogen Inhibitors Modulator
- 5.6.1. Selective Estrogen Inhibitors Modulator Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Rank Ligand Inhibitor
- 5.7.1. Rank Ligand Inhibitor Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Others
- 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Osteoporosis Drugs Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Osteoporosis Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacy
- 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacy
- 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online
- 6.5.1. Online Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Global Osteoporosis Drugs Market: Regional Estimates & Trend Analysis

7.1. Global Osteoporosis Drugs Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
- 7.2.1. North America Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Italy Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Spain Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Norway Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. China
  - 7.4.2.1. China Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Japan
  - 7.4.3.1. Japan Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
  - 7.4.5.1. South Korea Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Australia
  - 7.4.6.1. Australia Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Saudi Arabia
  - 7.6.2.1. Saudi Arabia Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. UAE
  - 7.6.3.1. UAE Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. South Africa
  - 7.6.4.1. South Africa Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. Amgen Inc.
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Eli Lilly and Company
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Merck & Co., Inc.
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Novartis AG
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Pfizer Inc.
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. GlaxoSmithKline plc.
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Radius Health, Inc.
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. UCB S.A.
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. Teva Pharmaceutical Industries Ltd.
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Roche Holding AG
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/ Strategic Initiatives

Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Branded, Generics), By Type (Bisphosphates, Parathyroid Hormone Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030